In this online, randomized controlled trial (RCT), the participants will be randomized and allocated in 1:1 ratio to mobile phone-based intervention group or to the wait-list control group. Participants will receive a 12-week intervention with follow-up at week 26. The primary outcome includes biologically verified continuous smoking abstinence at week 26 after the quit date. The main secondary outcomes include seven-day point prevalence smoking abstinence at weeks 1, 2, 3, 4, 8, 12, 16, 20 and 26, self-reported continuous smoking abstinence at weeks 4, 8, 12, 16, 20 and 26 after the quit date. About 2000 smokers with willingness to make a quit attempt within a month from October 2022 to April 2023 or until the recruitment process is complete will be recruited. The final 26-week follow-up will be completed in November 2023. The trial results will be available by the end of 2023 .
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
2,000
Participants in intervention group will receive a 12-week mobile phone-based intervention with follow-up at week 26.
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Hangzhou, Zhejiang, China
Continuous smoking abstinence
biologically verified continuous smoking abstinence at week 26 after the quit date
Time frame: at week 26 after the quit date
7-day point prevalence smoking abstinence
seven-day point prevalence smoking abstinence at weeks 1, 2, 3, 4, 8, 12, 16, 20 and 26
Time frame: week 1, 2, 3, 4, 8, 12, 16, 20 and 26
self-reported continuous smoking abstinence
self-reported continuous smoking abstinence at weeks 4, 8, 12, 16, 20 and 26 after the quit date
Time frame: week 4, 8, 12, 16, 20 and 26 after the quit date
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.